- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1309357-15-0] Silmitasertibsodiumsalt
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-50855B |
| Brand: | MCE |
| CAS: | 1309357-15-0 |
Overview
| MDL | MFCD28385881 |
|---|---|
| Molecular Weight | 371.75 |
| Molecular Formula | C19H11ClN3NaO2 |
| SMILES | O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)O[Na] |
16 Publications Citing Use of MCE
- [1]Science. 2017 Dec 1;358(6367):eaan4368.
- [2]Nat Cell Biol. 2021 Mar;23(3):257-267.
- [3]Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- [4]Nat Commun. 2023 Feb 9;14(1):731.
- [5]EMBO Mol Med. 2020 Aug 7;12(8):e11987.
- [6]Oncogene. 2022 Jan;41(4):571-585.
- [7]Oncogene. 2017 Aug 24;36(34):4943-4950.
- [8]Cancers (Basel). 2021, 13(5), 1127.
- [9]Int J Mol Sci. 2021 Jan 15;22(2):E819.
- [10]Int J Mol Sci. 2020 Mar 3;21(5):1718.
- [11]Cells. 2021 Jan 18;10(1):E181.
- [12]Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14.
- [13]Oncol Rep. 2017 Feb;37(2):1141-1147.
- [14]Biochem Biophys Res Commun. 2020 Oct 20;531(3):409-415.
- [15]Patent. US20180263995A1.
- [16]Oncotarget. 2016 Aug 16;7(33):53191-53203.
Summary
Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC 50 values of 1 nM against CK2α and CK2α'.
IC50 & Target
|
CK2α 1 nM (IC 50 ) |
CK2α' 1 nM (IC 50 ) |
In Vitro
Silmitasertib (CX-4945) causes cell-cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells, attenuates PI3K/Akt signalingand, and the antiproliferative activity of Silmitasertib (CX-4945) is correlated with expression levels of the CK2α catalytic subunit, Attenuation of PI3K/Akt signaling [1] . Silmitasertib (CX-4945) with PS-341 treatment prevents leukemic cells from engaging a functional UPR in order to buffer the PS-341-mediated proteotoxic stress in ER lumen, and decreases pro-survival ER chaperon BIP/Grp78 expression [2] . Silmitasertib (CX-4945) induces cytotoxicity and apoptosis, and exerts anti-proliferative effects in hematological tumors by downregulating CK2 expression and suppressing activation of CK2-mediated PI3K/Akt/mTOR signaling pathways [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Silmitasertib (CX-4945) (25 or 75 mg/kg, p.o.) is well tolerated and demonstrated robust antitumor activity with concomitant reductions of the mechanism-based biomarker phospho-p21 (T145) in murine xenograft models [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03904862 | Pediatric Brain Tumor Consortium|St. Jude Children´s Research Hospital|National Cancer Institute (NCI) |
Medulloblastoma, Childhood
|
March 18, 2019 | Phase 1|Phase 2 |
| NCT01199718 | Cylene Pharmaceuticals |
Multiple Myeloma
|
September 2010 | Phase 1 |
| NCT04668209 | University of Arizona|Senhwa Biosciences, Inc. |
Coronavirus
|
January 1, 2021 | Phase 2 |
| NCT04663737 | Chris Recknor, MD|Senhwa Biosciences, Inc. |
Covid19
|
December 3, 2020 | Phase 2 |
| NCT02128282 | Senhwa Biosciences, Inc. |
Cholangiocarcinoma
|
June 2014 | Phase 1|Phase 2 |
| NCT03897036 | Senhwa Biosciences, Inc. |
Carcinoma, Basal Cell
|
April 1, 2019 | Phase 1 |
| NCT00891280 | Cylene Pharmaceuticals |
Advanced Solid Tumors|Breast Cancer|Inflammatory Breast Cancer|Castleman´s Disease|Multiple Myeloma
|
February 2009 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 16.67 mg/mL ( 44.84 mM ; Need ultrasonic)
DMSO : 6.67 mg/mL ( 17.94 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.6900 mL | 13.4499 mL | 26.8998 mL |
| 5 mM | 0.5380 mL | 2.6900 mL | 5.3800 mL |
| 10 mM | 0.2690 mL | 1.3450 mL | 2.6900 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (67.25 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.60 mM); Clear solution
References
- [1] Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.
- [2] Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203.
- [3] Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40.
- [4] Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.